Angiotensin receptor blockers (ARBs) are widely used antihypertensive drugs that help reduce the cardiovascular and cerebrovascular risks and renal complications in patients with hypertension. Telmisartan has been shown to improve renal endothelial function, prevent progression from microalbuminuria to macroalbuminuria, slow the decline in glomerular filtration rate, and reduce proteinuria in overt nephropathy. Combination of an ARB and an ACE inhibitor is not recommended as it is associated with an excess of adverse renal events. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. Listen to the expert to know more on the ARB in Diabetes
